Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

References

• Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr. 2020;150(4):663–671. doi:10.1093/jn/nxz268
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii56–vii64. doi:10.1093/annonc/mds226
   PubMed Web of Science ®Google Scholar
• Cetin K, Ettinger DS, Hei YJ, O’Malley CD. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program. Clin Epidemiol. 2011;3:139–148. doi:10.2147/CLEP.S17191
   PubMedGoogle Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. doi:10.1016/j.annonc.2020.04.478
   PubMed Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–943. doi:10.1056/NEJMoa2004407
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi:10.1056/NEJMoa2002787
   PubMed Web of Science ®Google Scholar
• Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–526. doi:10.1038/431525b
   PubMed Web of Science ®Google Scholar
• Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–475. doi:10.1038/nrc2656
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111–128.
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004;15(1):19–27. doi:10.1093/annonc/mdh031
   PubMed Web of Science ®Google Scholar
• Krug LM, Miller VA, Patel J, et al. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer. 2005;104(10):2149–2155. doi:10.1002/cncr.21428
   PubMed Web of Science ®Google Scholar
• Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5(12):1922–1932. doi:10.1097/JTO.0b013e3181f26266
   PubMed Web of Science ®Google Scholar
• Arcila ME, Chaft JE, Nafa K, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012;18(18):4910–4918. doi:10.1158/1078-0432.CCR-12-0912
   PubMed Web of Science ®Google Scholar
• Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6(11):e28204. doi:10.1371/journal.pone.0028204
   PubMed Web of Science ®Google Scholar
• Li C, Sun Y, Fang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol. 2012;7(1):85–89. doi:10.1097/JTO.0b013e318234f0a2
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997–2003. doi:10.1200/JCO.2012.45.6095
   PubMed Web of Science ®Google Scholar
• Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 2011;74(1):139–144. doi:10.1016/j.lungcan.2011.01.014
   PubMed Web of Science ®Google Scholar
• Yoshizawa A, Sumiyoshi S, Sonobe M, et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer. 2014;85(3):373–378. doi:10.1016/j.lungcan.2014.06.007
   PubMed Web of Science ®Google Scholar
• Chen RZJ, Lin G, Liu L, Chen L, Hu X. NGS sequencing based liquid/tissue biopsy identified coexistence of HER2 amplification and mutation in advanced NSCLC patients. J Thorac Oncol. 2017;12(11):S1830. doi:10.1016/j.jtho.2017.09.513
   Google Scholar
• Li BT, Ross DS, Aisner DL, et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol. 2016;11(3):414–419. doi:10.1016/j.jtho.2015.10.025
   PubMed Web of Science ®Google Scholar
• Nagano M, Kohsaka S, Ueno T, et al. High-throughput functional evaluation of variants of unknown significance in ERBB2. Clin Cancer Res. 2018;24(20):5112–5122. doi:10.1158/1078-0432.CCR-18-0991
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25–38. doi:10.1016/j.ccr.2006.05.023
   PubMed Web of Science ®Google Scholar
• Fang W, Zhao S, Liang Y, et al. Mutation variants and co-mutations as genomic modifiers of response to afatinib in HER2-mutant lung adenocarcinoma. Oncologist. 2020;25(3):e545.
   PubMed Web of Science ®Google Scholar
• Notsuda H, Bradbury PA, Tsao MS. HER2 transmembrane domain mutations: rare new target for non-small cell lung cancer therapy. J Thorac Oncol. 2017;12(3):422–424. doi:10.1016/j.jtho.2017.01.007
   PubMed Web of Science ®Google Scholar
• Ou SI, Schrock AB, Bocharov EV, et al. HER2 Transmembrane Domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. J Thorac Oncol. 2017;12(3):446–457. doi:10.1016/j.jtho.2016.11.2224
   PubMed Web of Science ®Google Scholar
• Wei XW, Gao X, Zhang XC, et al. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac Cancer. 2020;11(6):1512–1521. doi:10.1111/1759-7714.13419
   PubMed Web of Science ®Google Scholar
• Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA. 2012;109(36):14476–14481. doi:10.1073/pnas.1203201109
   PubMed Web of Science ®Google Scholar
• Ni J, Si XY, Zhang L. Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: a case report. Thorac Cancer. 2021;12(8):1244–1247. doi:10.1111/1759-7714.13889
   PubMed Web of Science ®Google Scholar
• Liu Z, Wu L, Cao J, et al. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients. Onco Targets Ther. 2018;11:7323–7331. doi:10.2147/OTT.S173391
   PubMed Web of Science ®Google Scholar
• Yuan B, Zhao J, Zhou C, et al. Co-occurring alterations of ERBB2 exon 20 insertion in Non-Small Cell Lung Cancer (NSCLC) and the potential indicator of response to afatinib. Front Oncol. 2020;10:729. doi:10.3389/fonc.2020.00729
   PubMed Web of Science ®Google Scholar
• De Greve J, Moran T, Graas M-P, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer. 2015;88(1):63–69. doi:10.1016/j.lungcan.2015.01.013
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Smit EF, Dafni U, et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol. 2019;14(6):1086–1094. doi:10.1016/j.jtho.2019.02.017
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa Multiple Basket Study. J Clin Oncol. 2018;36(6):536–542. doi:10.1200/JCO.2017.75.3780
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–194. doi:10.1038/nature25475
   PubMed Web of Science ®Google Scholar
• Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26(7):1421–1427. doi:10.1093/annonc/mdv186
   PubMed Web of Science ®Google Scholar
• Lai WV, Lebas L, Barnes TA, et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. Eur J Cancer. 2019;109:28–35. doi:10.1016/j.ejca.2018.11.030
   PubMed Web of Science ®Google Scholar
• Li BT, Shen R, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–2537. doi:10.1200/JCO.2018.77.9777
   PubMed Web of Science ®Google Scholar
• Peters S, Curioni-Fontecedro A, Nechushtan H, et al. Activity of afatinib in heavily pretreated patients with ERBB2 mutation-positive advanced NSCLC: findings from a global named patient use program. J Thorac Oncol. 2018;13(12):1897–1905. doi:10.1016/j.jtho.2018.07.093
   PubMed Web of Science ®Google Scholar
• Peters S, Stahel R, Bubendorf L, et al. Trastuzumab Emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64–72. doi:10.1158/1078-0432.CCR-18-1590
   PubMed Web of Science ®Google Scholar
• Robichaux JP, Elamin YY, Tan Z, et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018;24(5):638–646. doi:10.1038/s41591-018-0007-9
   PubMed Web of Science ®Google Scholar
• Smit EFNK, Nagasaka M. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer: interim results of DESTINY-lung01[abstract]. J Clin Oncol. 2020;38(Abstract):9504. doi:10.1200/JCO.2020.38.15_suppl.9504
   Google Scholar
• Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, Phase I Study in multiple advanced solid tumors. Cancer Discov. 2020;10(5):688–701. doi:10.1158/2159-8290.CD-19-1014
   PubMed Web of Science ®Google Scholar
• Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 2019;30(3):447–455. doi:10.1093/annonc/mdy542
   PubMed Web of Science ®Google Scholar
• Zhou C, Li X, Wang Q, et al. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, Phase II Study. J Clin Oncol. 2020;38(24):2753–2761. doi:10.1200/JCO.20.00297
   PubMed Web of Science ®Google Scholar
• De Greve J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123–127. doi:10.1016/j.lungcan.2012.01.008
   PubMed Web of Science ®Google Scholar
• Ivanova EBM, Aref A, Chen T, Taus L, Avogadri-Connors F. Short-term culture of patient derived tumor organoids identify neratinib/trastuzumab as an effective combination in HER2 mutant lung cancer. J Thorac Oncol. 2017;12(11):S1829–S1830. doi:10.1016/j.jtho.2017.09.512
   Web of Science ®Google Scholar
• Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26(10):2073–2078. doi:10.1093/annonc/mdv319
   PubMed Web of Science ®Google Scholar
• Liu S, Li S, Hai J, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res. 2018;24(11):2594–2604. doi:10.1158/1078-0432.CCR-17-1875
   PubMed Web of Science ®Google Scholar
• Park YH, Lee KH, Sohn JH, et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int J Cancer. 2018;143(12):3240–3247. doi:10.1002/ijc.31651
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597–609. doi:10.1056/NEJMoa1914609
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the herceptin fab. Nature. 2003;421(6924):756–760. doi:10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Mazieres J, Barlesi F, Filleron T, et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016;27(2):281–286. doi:10.1093/annonc/mdv573
   PubMed Web of Science ®Google Scholar
• Hotta K, Aoe K, Kozuki T, et al. A Phase II Study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13(2):273–279. doi:10.1016/j.jtho.2017.10.032
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi:10.6004/jnccn.2021.0013
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a Phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522. doi:10.1016/S1470-2045(17)30604-6
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. doi:10.1093/annonc/mdz167
   PubMed Web of Science ®Google Scholar
• Lin JJ, Gainor JF. Time to tackle the blood-brain barrier in HER2-mutant lung cancer. Cancer. 2019;125(24):4363–4366. doi:10.1002/cncr.32460
   PubMed Web of Science ®Google Scholar
• Hsu CC, Liao BC, Liao WY, et al. Exon 16-skipping HER2 as a novel mechanism of osimertinib resistance in EGFR L858R/T790M-positive non-small cell lung cancer. J Thorac Oncol. 2020;15(1):50–61. doi:10.1016/j.jtho.2019.09.006
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(9):841–849. doi:10.1200/JCO.2017.74.7576
   PubMed Web of Science ®Google Scholar
• Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 2014;3(2):84–88. doi:10.3978/j.issn.2218-6751.2014.02.06
   PubMedGoogle Scholar
• Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of cancer and leukemia group B. Cancer. 2005;103(8):1670–1675. doi:10.1002/cncr.20950
   PubMed Web of Science ®Google Scholar
• Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20(14):3095–3105. doi:10.1200/JCO.2002.09.094
   PubMed Web of Science ®Google Scholar
• Al-Saad S, Al-Shibli K, Donnem T, Andersen S, Bremnes RM, Busund LT. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J Thorac Oncol. 2010;5(10):1536–1543. doi:10.1097/JTO.0b013e3181ea510a
   PubMed Web of Science ®Google Scholar
• Gazzaniga P, Gradilone A, Frati L, Agliano AM. Epidermal growth factor receptor mRNA expression in peripheral blood of bladder cancer patients: a potential marker to detect treatment failure. Clin Cancer Res. 2001;7(12):4288–4289.
   PubMed Web of Science ®Google Scholar
• Ross HJ, Blumenschein GR Jr, Aisner J, et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010;16(6):1938–1949. doi:10.1158/1078-0432.CCR-08-3328
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20(2):298–304. doi:10.1093/annonc/mdn635
   PubMed Web of Science ®Google Scholar
• Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922–933. doi:10.1158/2159-8290.CD-12-0108
   PubMed Web of Science ®Google Scholar
• Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–1400. doi:10.1038/nm.3388
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86. doi:10.1126/scitranslmed.3002442
   PubMed Web of Science ®Google Scholar
• Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–2247. doi:10.1158/1078-0432.CCR-12-2246
   PubMed Web of Science ®Google Scholar
• Ramalingam SSCY, Zhou C, Ohe Y, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the Phase III FLAURA study. Ann Oncol. 2018. doi:10.1093/annonc/mdy424.063
   Google Scholar
• Xu CWW, Zhu Y, Yu Z, Zhang H, Wang H. Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ nonsmall cell lung cancer patients with primary resistance to osimertinib: a multicenter study. Ann Oncol. 2019;30:ii48.
   Web of Science ®Google Scholar
• Martin V, Landi L, Molinari F, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013;108(3):668–675. doi:10.1038/bjc.2013.4
   PubMed Web of Science ®Google Scholar
• Hotta K, Yanai H, Ohashi K, et al. Pilot evaluation of a HER2 testing in non-small-cell lung cancer. J Clin Pathol. 2020;73(6):353–357. doi:10.1136/jclinpath-2019-206204
   PubMed Web of Science ®Google Scholar
• Kuyama S, Hotta K, Tabata M, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(5):477–482. doi:10.1097/JTO.0b013e31816e2ea3
   PubMed Web of Science ®Google Scholar
• Ninomiya K, Hata T, Yoshioka H, et al. A Prospective Cohort Study to define the clinical features and outcome of lung cancers harboring HER2 aberration in Japan (HER2-CS STUDY). Chest. 2019;156(2):357–366. doi:10.1016/j.chest.2019.01.011
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001;7(10):3239–3250.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group S. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22(7):1180–1187. doi:10.1200/JCO.2004.04.105
   PubMed Web of Science ®Google Scholar
• Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007;13(20):6175–6181. doi:10.1158/1078-0432.CCR-07-0460
   PubMed Web of Science ®Google Scholar
• Johnson BE, Janne PA. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12(14 Pt 2):4436s–4440s. doi:10.1158/1078-0432.CCR-06-0629
   PubMed Web of Science ®Google Scholar
• de Langen AJ, Jebbink M, Hashemi SMS, et al. Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment. Br J Cancer. 2018;119(5):558–564. doi:10.1038/s41416-018-0194-7
   PubMed Web of Science ®Google Scholar
• Cretella D, Saccani F, Quaini F, et al. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Mol Cancer. 2014;13:143. doi:10.1186/1476-4598-13-143
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Hackshaw A, Ngai Y, et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014;12(7):e1001906. doi:10.1371/journal.pbio.1001906
   PubMed Web of Science ®Google Scholar
• La Monica S, Cretella D, Bonelli M, et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. J Exp Clin Cancer Res. 2017;36(1):174. doi:10.1186/s13046-017-0653-7
   PubMedGoogle Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar